Marlon Torrento, MD
Infectious Disease · Festus, MONPI 1447416292
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Paratek Pharmaceuticals, Inc. at 45.2% of the total.
Across 34 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$283
- AbbVie$97
- Insmed, Inc.$83
- Cumberland Pharmaceuticals, Inc.$45
- Merck$44
- Nestle Healthcare Nutrition Inc.$43
- plus $31 from 2 others
What the payments were for
- Food & beverage$627100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 16 | $283 |
| AbbVie(2 entities) | 6 | $97 |
| Insmed, Inc. | 4 | $83 |
| Cumberland Pharmaceuticals, Inc. | 2 | $45 |
| Merck | 2 | $44 |
| Nestle Healthcare Nutrition Inc. | 2 | $43 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
How this compares
$627 in reported general payments places this provider in the 60th percentile of 177 infectious disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErtapenemErtapenem Sodium | 13 | $6,002 |
| Ampicillin Sodium | 19 | $4,775 |
| Vancomycin Hcl | 41 | $4,435 |
| Meropenem | 19 | $3,149 |
| Doxycycline Hyclate | 140 | $2,577 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 108 | $1,958 |
| Clindamycin Hcl | 28 | $1,318 |
| Cefdinir | 43 | $1,047 |
| Cephalexin | 62 | $1,001 |
| Sodium Chloride0.9 % Sodium Chloride | 21 | $666 |
| CeftriaxoneCeftriaxone Sodium | 18 | $639 |
| Ciprofloxacin Hcl | 22 | $255 |
| Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod | 13 | $244 |
| Fluconazole | 18 | $194 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Festus
- Robert BelsheSaint Louis$382K
- Erik DubberkeSaint Louis$144K
- Rupa PatelSaint Louis$96K
- Michael DiamondSaint Louis$44K
- Nirmol PhilipChesterfield$31K
- Andrej SpecSaint Louis$26K
- William PowderlySaint Louis$20K
- Daniel HoftSt Louis$20K
- Matthew GermanChesterfield$16K
- Elvin GengSaint Louis$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.